Regeneron and Sanofi to Present Phase 3 Praluent® (alirocumab) Injection Clinical Trial Data at ACC.16

You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

Continue

Release Details

Regeneron and Sanofi to Present Phase 3 Praluent® (alirocumab) Injection Clinical Trial Data at ACC.16